Dostarlimab is primarily indicated for the treatment of specific types of endometrial cancer, often used in combination with other therapeutic agents. This targeted immunotherapy plays a crucial role in managing advanced or recurrent forms of the disease.
Dostarlimab Indications
Dostarlimab is an immune checkpoint inhibitor approved for the treatment of certain patients with endometrial cancer, a type of cancer that begins in the lining of the uterus. Its use is contingent upon specific molecular characteristics of the tumor, making it a personalized treatment option.
Specific Treatment Scenarios for Dostarlimab
Dostarlimab is used in the following specific clinical contexts:
- Used in combination to treat advanced, primary endometrial cancer.
- Used in combination to treat recurrent microsatellite instability (MSI)-high endometrial cancer.
- Used in combination to treat recurrent mismatch repair-deficient (dMMR) endometrial cancer.
These indications highlight the importance of biomarker testing (for MSI-high and dMMR status) to identify patients most likely to benefit from dostarlimab therapy. The "in combination to treat" aspect signifies that it is typically administered alongside other treatments, rather than as a standalone therapy, for these indications.
Summary of Dostarlimab Indications
For an easy overview, the indications for dostarlimab are summarized below:
| Indication Type | Indication |
|---|---|
| Used in combination to treat | Advanced, primary endometrial cancer |
| Used in combination to treat | Recurrent microsatellite instability (MSI)-high endometrial cancer |
| Used in combination to treat | Recurrent mismatch repair-deficient (dMMR) endometrial cancer |
Understanding these specific indications is vital for healthcare professionals in determining appropriate treatment strategies for patients with endometrial cancer. For more detailed information on dostarlimab, including its mechanism of action and potential interactions, you can refer to resources like DrugBank.
